Our MAGE-A4 SPEAR T-cell therapy is directed to a member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types.  An IND for our MAGE-A4 SPEAR T-cell program in urothelial (bladder) cancers, melanoma, head and neck cancer, ovarian cancer, NSCLC, esophageal cancer and gastric cancers is now open.